After the Kefauver Harris Amendment was passed in 1962, the . FDA began the DESI review process to ensure the safety and efficacy of drugs approved under the more lenient pre-1962 standards, including Dianabol.  In 1965, the FDA pressured CIBA to further document its legitimate medical uses, and re-approved the drug for treating post-menopausal osteoporosis and pituitary-deficient dwarfism .  After CIBA's patent exclusivity period lapsed, other manufacturers began to market generic metandienone in the .
Nandrolone decanoate in the form of the Organon product, Deca-Durabolin, has been around for over 30 years. It has anabolic, androgenic, progestogenic and erythropoietic activity. The steroid maintains the anabolic activity of testosterone but the androgenic action is markedly diminished. The anabolic/androgenic quotient after 2 weeks of treatment has been shown to be 12 times that obtained with testosterone decanoate. Nandrolone decanoate has been shown to influence calcium metabolism positively and to increase bone mass in osteoporosis. Androgenic effects are relatively uncommon at the recommended therapeutic dosages.